Catalent to Discuss Ways of Increasing Accuracy and Speed in Assay Development at CASSS WCBP Symposium

Tuesday, January 21, 2020 Press Release
Email Print This Page Comment bookmark
Font : A-A+

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Christopher Hepler, Manager, Catalent Biologics Analytical Development, has been invited to speak on ways to improve assay development at the upcoming CASSS WCBP symposium, which will be held at the Mayflower Hotel, Washington, D.C. on Jan 28 - 30, 2020.

SOMERSET, N.J., Jan. 21, 2020 /PRNewswire-PRWeb/ -- Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Christopher Hepler, Manager, Catalent Biologics Analytical Development, has been invited to speak on ways to improve assay development at the upcoming CASSS WCBP symposium, which will be held at the Mayflower Hotel, Washington, D.C. on Jan 28 – 30, 2020.

On Tuesday, Jan. 28 at 12:50 p.m., Mr. Hepler will present "Conversion of a Potency Assay from Cell-Based Binding to AlphaLISA®"*, and using a case study, explain how the AlphaLISA® platform can develop a relative potency assay that, is more accurate, quicker and easier to execute than the original FACS-based assay.

Mr. Hepler received his bachelor's degree in animal science and master's degree in physiology from North Carolina State University, and has been working in the pharmaceutical and biopharmaceutical industry for more than 25 years. He is experienced in automation, as well as cell and molecular biology assay development, optimization, and validation. Mr. Hepler joined Catalent in 2016, and in his current role, manages the Biologics department for the Morrisville, RTP site.

For further information on this event, visit http://www.catalent.com/events/casss-wcbp/

To arrange a meeting with Mr. Hepler or any of the other Catalent experts attending the event, contact Richard Kerns at NEPR – richard@nepr.agency

*AlphaLISA is a registered trademark of PerkinElmer LAS, Inc.

About Catalent Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

 

SOURCE Catalent



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store